NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, ...
Results of the first interim analysis of the CARMA study to investigate efficacy and safety profile of catumaxomab in clinical practice. This is an ASCO Meeting Abstract from the 2012 ASCO Annual ...
Adding the measurement of cystatin C to that of serum creatinine to determine the estimated glomerular filtration rate (eGFR) improves accuracy, but the effect on detection, staging, and risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results